A Study of HGS1029 (AEG40826-2HCl) in Subjects With Advanced Solid Tumors

A Phase 1 Dose-Escalation Study to Evaluate the Safety and Tolerability of HGS1029 (AEG40826-2HCl) in Patients With Advanced Solid Tumors

The purpose of this study is to evaluate the safety and tolerability of HGS1029 in subjects with advanced solid tumors and to determine a phase 2 dose.

Inclusion Criteria:

• Confirmed advanced solid malignancy
• Life expectancy of at least 3 months
• Age 18 years or older
• Acceptable liver function
• Acceptable renal function
• Acceptable hematologic status

Exclusion Criteria:

• Received investigational (not yet approved by a regulatory authority)agent within 4 weeks before enrollment.
• Received non-investigational agent within 3 weeks before enrollment.
• Progressive CNS involvement including the need of corticosteroids
• Pregnant or breast-feeding women
• Active, uncontrolled bacterial, viral, or fungal infections within 2 weeks of Cycle 1 Day 1
• Known HIV infection